Overview

The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.

Status:
Completed
Trial end date:
2020-08-30
Target enrollment:
Participant gender:
Summary
The COVID-19 pandemic is of grave concern due its impact on human health and on the economy. Propolis, a natural resin produced by bees from plant materials, has anti-inflammatory, immunomodulatory, anti-oxidant properties, and various aspects of the SARS-CoV-2 infection mechanism are potential targets for propolis compounds. Propolis components have inhibitory effects on the ACE2, TMPRSS2 and PAK1 signaling pathways; in addition, antiviral activity has been proven in vitro and in vivo. This is a pilot randomized study that aims to assess the impact of using Brazilian green propolis extract against the deleterious effects of the new coronavirus.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
D'Or Institute for Research and Education
Collaborator:
Hospital Sao Rafael
Treatments:
Propolis